Related to FDA and EMA Take Steps to Restrict Avastin Use in Breast Cancer

• EC Approves Novartis’ Cushing Disease Therapy Signifor
  
• Takeda’s Type 2 Diabetes Therapies Set Back Again by FDA
  
• FDA Requests More Risk-Benefit Data for Amgen’s Xgeva sBLA in Prostate Cancer
  
• Novartis’ Afinitor Gets FDA Okay for Treating Renal Angiomyolipoma Associated with TSC
  
• GSK’s Votrient Approved in U.S. for Treating Soft Tissue Sarcoma
  
• EC Sanctions Pharmaxis’ Bronchitol as Add-On Therapy for Cystic Fibrosis
  
• Protalix, Pfizer Report FDA Approval of Plant-Derived Gaucher Disease ERT Elelyso
  
• EC Conditionally Approves Cell Therapeutics’ Pixantrone for Non-Hodgkin Lymphoma
  
• Curetis Wins CE Mark for POC Diagnostic Platform, Pneumonia Test Cartridge
  
• IntelligentMDx Wins CE Mark for Group B Strep Assay on Abbott m2000 Instrument
  
• BioDelivery Earns $2.5M from Meda on Pricing Approval of Breakyl in First EU Country
  
• FDA Clears Novo Nordisk’s Levemir for Diabetic Children Aged Two Years and Over
  
• FDA Approves XenoPort, GSK’s Horizant for Managing Postherpetic Neuralgia
  
• FDA Clears Immunetics' Rapid Test for Bacterial Contamination of Platelet Units
  
• FDA Approves GSK’s MenHibrix Meningitis Vaccine
  
• Multiplicom Achieves CE Mark for BRCA1&2 Gene Mutation In Vitro Diagnostic
  
• FDA Clears Pfizer’s Lyrica for Spinal Cord Injury Neuropathic Pain
  
• FDA Fails to Back Janssen, Bayer’s Xarelto for Acute Coronary Syndrome
  
• BMS, Pfizer Fail to Win FDA Sanction for Stroke Prevention Drug
  
• FDA Clears Baxter’s Gammagard for Multifocal Motor Neuropathy